A 42-year-old woman with spinocerebellar ataxia type 1 (SCA1) presents with progressive ataxia, nystagmus, and dysarthria over the past 2 years. She has difficulty with balance and coordination. Genetic testing confirms the diagnosis. What is the most appropriate next step in management?

Explanation

## Understanding Spinocerebellar Ataxias (SCAs) **Key Point:** Spinocerebellar ataxias are autosomal dominant neurodegenerative disorders caused by trinucleotide repeat expansions. SCA1 involves CAG repeats in the ATXN1 gene, leading to progressive cerebellar and brainstem degeneration. **High-Yield:** There is NO disease-modifying therapy for SCA1. Management is purely symptomatic and supportive. Genetic counseling is essential as this is an autosomal dominant condition with 50% inheritance risk to offspring. ## Why Physiotherapy + Genetic Counseling is Correct ### Symptomatic Management 1. **Physiotherapy** — maintains balance, coordination, and functional mobility 2. **Occupational therapy** — adapts environment, teaches compensatory strategies 3. **Speech therapy** — addresses dysarthria 4. **Assistive devices** — walkers, canes reduce fall risk ### Genetic Counseling - Autosomal dominant inheritance (50% risk to each child) - Anticipation phenomenon — earlier onset and severity in successive generations - Prenatal and preimplantation genetic diagnosis options - Family members should be screened and counseled **Clinical Pearl:** SCA1 patients typically become wheelchair-dependent by 15–20 years post-onset. Early rehabilitation maximizes functional independence and quality of life. ## Management Approach for SCAs ```mermaid flowchart TD A[Confirmed SCA diagnosis]:::outcome --> B[Genetic counseling]:::action A --> C[Symptomatic management]:::action C --> D[Physiotherapy & OT]:::action C --> E[Speech therapy]:::action C --> F[Assistive devices]:::action B --> G[Family screening]:::action D --> H[Maintain function & QOL]:::outcome ``` ## Why Other Options Are Incorrect | Option | Why Wrong | |--------|----------| | **Levodopa** | Effective only in Parkinson disease (dopamine-responsive). SCAs involve cerebellar degeneration, not dopamine deficiency. No role in SCA1. | | **Intrathecal baclofen** | Baclofen is for spasticity (upper motor neuron signs). SCA1 causes cerebellar ataxia (coordination loss), not spasticity. Inappropriate drug for the pathophysiology. | | **Corticosteroids** | No evidence for slowing neurodegeneration in SCAs. Chronic steroids cause harm (osteoporosis, immunosuppression) without benefit. | **Mnemonic:** **SAFE management of SCAs** = **S**upport (physiotherapy), **A**ssistive devices, **F**amily counseling, **E**arly intervention.